Abbott Laboratories (ABT.N)
85.48USD
6 Dec 2019
$0.24 (+0.28%)
$85.24
$85.67
$85.91
$85.39
1,086,662
1,458,980
$88.76
$65.44
About
Buy/Sell
Overall
Beta: | 1.57 |
Market Cap(Mil.): | $95,559.38 |
Shares Outstanding(Mil.): | 1,737.44 |
Dividend: | 0.26 |
Yield (%): | 1.93 |
Stents no better than drugs for many heart patients -U.S. study
CHICAGO, Nov 16 Many patients with severe but stable heart disease who routinely undergo invasive procedures to clear and prop open clogged arteries would do as well by just taking medications and making lifestyle changes, U.S. researchers reported on Saturday.
PRESS DIGEST - Wall Street Journal - Nov 14
Nov 14 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
Abbott CEO Miles White to step down next year
Abbott Laboratories longtime Chief Executive Officer Miles White will step down in favour of his chief of operations in March, handing over the reins after successfully reshaping the healthcare conglomerate in a series of transformative deals.
Abbott CEO Miles White to step down next year
Abbott Laboratories longtime Chief Executive Officer Miles White will step down in favor of his chief of operations in March, handing over the reins after successfully reshaping the healthcare conglomerate in a series of transformative deals.
UPDATE 2-Abbott CEO Miles White to step down next year
Nov 13 Abbott Laboratories longtime Chief Executive Officer Miles White will step down in favor of his chief of operations in March, handing over the reins after successfully reshaping the healthcare conglomerate in a series of transformative deals.
Abbott CEO Miles White to step down next year
Nov 13 Abbott Laboratories said on Wednesday Chief Executive Officer Miles White would step down next year and be replaced by Chief Operating Officer Robert Ford.
UPDATE 2-FDA classifies Abbott's blood pumping system recall as most serious
Nov 4 The U.S. Food and Drug Administration on Monday classified the recall of Abbott Laboratories' CentriMag blood pumping system following the death of a patient, as Class 1 or the most serious type of recall.
FDA classifies Abbott's blood pumping system recall as most serious
Nov 4 The U.S. Food and Drug Administration on Monday classified the recall of Abbott Laboratories' CentriMag blood pumping system, following the death of a patient, as Class 1 or the most serious type of recall.
Abbott revenue misses as heart devices eclipse diabetes gains
Abbott Laboratories fell just short of Wall Street estimates for quarterly revenue on Wednesday, as weakness in the medical device maker's cardiovascular business overshadowed strong performance in its fast-growing diabetes care unit.
Märkte
- U.S.
- Europa
- Asien
- Branchen
DOW | 28,015.06 |
![]() |
+1.22% |
S&P 500 | 3,145.91 |
![]() |
+0.91% |
NASDAQ | 8,656.53 |
![]() |
+1.00% |
TR US Index | 277.48 |
![]() |
+1.03% |
Rohstoffe
Gold | 1,458.40 | -18.50 | -1.25% |
Oil | 59.07 | +0.64 | +1.10% |
Corn | 366.50 | +1.00 | +0.27% |
Rohstoffe
Gold | 1,458.40 | -18.50 | -1.25% |
Oil | 59.07 | +0.64 | +1.10% |
Corn | 366.50 | +1.00 | +0.27% |
Rohstoffe
Gold | 1,458.40 | -18.50 | -1.25% |
Oil | 59.07 | +0.64 | +1.10% |
Corn | 366.50 | +1.00 | +0.27% |
Branchenüberblick
Energie |
![]() |
Rohstoffe |
![]() |
Industrie |
![]() |
Konjunktur abhängige Waren & Dienstleistungen |
![]() |
Konjunktur unabhängige Waren & Dienstleistungen |
![]() |
Finanzindustrie |
![]() |
Pharma |
![]() |
Technologie |
![]() |
Telekommunikation |
![]() |
Nachrichten aus der Wirtschaft
Schweizer Börse legt zu - Swiss Re nach Spartenverkauf gesucht
Zürich Gute US-Konjunkturdaten haben der Schweizer Börse zum Wochenschluss Schub verliehen. Der SMI gewann rund ein Prozent auf 10.463 Punkte. Der stärkste Stellenaufbau in den USA seit zehn Monaten zeigte Händler zufolge, dass der US-Arbeitsmarkt in besserer Verfassung ist erwartet. Trotz des Schlussspurts verbuchte der Leitindex im Verlauf der gesamten Woche ein Minus von rund 0,3 Prozent.